These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 16781214

  • 1. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424.
    Boden WE, O'rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GB, Berman DS, Weintraub WS, COURAGE trial coprincipal investigators and study coordinators.
    Am Heart J; 2006 Jun; 151(6):1173-9. PubMed ID: 16781214
    [Abstract] [Full Text] [Related]

  • 2. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
    Teo KK, Sedlis SP, Boden WE, O'Rourke RA, Maron DJ, Hartigan PM, Dada M, Gupta V, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS, COURAGE Trial Investigators.
    J Am Coll Cardiol; 2009 Sep 29; 54(14):1303-8. PubMed ID: 19778673
    [Abstract] [Full Text] [Related]

  • 3. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial).
    Boden WE, O'Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, Dada M, Labedi M, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS, COURAGE Trial Investigators.
    Am J Cardiol; 2009 Jul 01; 104(1):1-4. PubMed ID: 19576311
    [Abstract] [Full Text] [Related]

  • 4. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.
    Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE, COURAGE Investigators.
    Circulation; 2008 Mar 11; 117(10):1283-91. PubMed ID: 18268144
    [Abstract] [Full Text] [Related]

  • 5. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
    Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JA.
    Circulation; 2007 Mar 06; 115(9):1082-9. PubMed ID: 17339566
    [Abstract] [Full Text] [Related]

  • 6. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.
    Maron DJ, Spertus JA, Mancini GB, Hartigan PM, Sedlis SP, Bates ER, Kostuk WJ, Dada M, Berman DS, Shaw LJ, Chaitman BR, Teo KK, O'Rourke RA, Weintraub WS, Boden WE, COURAGE Trial Research Group.
    Am J Cardiol; 2009 Oct 15; 104(8):1055-62. PubMed ID: 19801024
    [Abstract] [Full Text] [Related]

  • 7. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design.
    Kapur A, Malik IS, Bagger JP, Anderson JR, Kooner JS, Thomas M, Punjabi P, Mayet J, Millane T, Goedicke J, Jamrozik K, de Belder MA, Hall RJ, Beatt KJ.
    Am Heart J; 2005 Jan 15; 149(1):13-9. PubMed ID: 15660030
    [Abstract] [Full Text] [Related]

  • 8. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial.
    Maron DJ, Boden WE, O'Rourke RA, Hartigan PM, Calfas KJ, Mancini GB, Spertus JA, Dada M, Kostuk WJ, Knudtson M, Harris CL, Sedlis SP, Zoble RG, Title LM, Gosselin G, Nawaz S, Gau GT, Blaustein AS, Bates ER, Shaw LJ, Berman DS, Chaitman BR, Weintraub WS, Teo KK, COURAGE Trial Research Group.
    J Am Coll Cardiol; 2010 Mar 30; 55(13):1348-58. PubMed ID: 20338496
    [Abstract] [Full Text] [Related]

  • 9. Optimal medical therapy is a proven option for chronic stable angina.
    O'Rourke RA.
    J Am Coll Cardiol; 2008 Sep 09; 52(11):905-7. PubMed ID: 18772059
    [Abstract] [Full Text] [Related]

  • 10. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials.
    Daemen J, Boersma E, Flather M, Booth J, Stables R, Rodriguez A, Rodriguez-Granillo G, Hueb WA, Lemos PA, Serruys PW.
    Circulation; 2008 Sep 09; 118(11):1146-54. PubMed ID: 18725490
    [Abstract] [Full Text] [Related]

  • 11. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase.
    Ong AT, Serruys PW, Mohr FW, Morice MC, Kappetein AP, Holmes DR, Mack MJ, van den Brand M, Morel MA, van Es GA, Kleijne J, Koglin J, Russell ME.
    Am Heart J; 2006 Jun 09; 151(6):1194-204. PubMed ID: 16781219
    [Abstract] [Full Text] [Related]

  • 12. Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial.
    Weintraub WS, Barnett P, Chen S, Hartigan P, Casperson P, O'Rourke R, Boden WE, Lewis C, Veledar E, Becker E, Culler S, Kolm P, Mahoney EM, Dunbar SB, Deaton C, O'Brien B, Goeree R, Blackhouse G, Nease R, Spertus J, Kaufman S, Teo K.
    Am Heart J; 2006 Jun 09; 151(6):1180-5. PubMed ID: 16781215
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients.
    Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG, Department of Veterans Affairs Cooperative Studies Program No. 424 (COURAGE Trial) Investigators and Study Coordinators.
    Circ Cardiovasc Qual Outcomes; 2008 Sep 09; 1(1):12-20. PubMed ID: 20031783
    [Abstract] [Full Text] [Related]

  • 14. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
    Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA, Stone GW.
    Am Heart J; 2009 Oct 09; 158(4):520-526.e2. PubMed ID: 19781409
    [Abstract] [Full Text] [Related]

  • 15. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Pastori F, De Luca L, Zavalloni D, Soregaroli D, Garbo R, Franchi E, Marino P, Minelli M, Vassanelli C.
    J Cardiovasc Med (Hagerstown); 2009 Feb 09; 10(2):192-9. PubMed ID: 19377384
    [Abstract] [Full Text] [Related]

  • 16. Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease.
    Javaid A, Steinberg DH, Buch AN, Corso PJ, Boyce SW, Pinto Slottow TL, Roy PK, Hill P, Okabe T, Torguson R, Smith KA, Xue Z, Gevorkian N, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R.
    Circulation; 2007 Sep 11; 116(11 Suppl):I200-6. PubMed ID: 17846304
    [Abstract] [Full Text] [Related]

  • 17. Clinical implications of the BARI 2D and COURAGE trials: the evolving role of percutaneous coronary intervention.
    Holper EM, Addo T.
    Coron Artery Dis; 2010 Nov 11; 21(7):397-401. PubMed ID: 20634692
    [Abstract] [Full Text] [Related]

  • 18. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial.
    Daemen J, Kuck KH, Macaya C, LeGrand V, Vrolix M, Carrie D, Sheiban I, Suttorp MJ, Vranckx P, Rademaker T, Goedhart D, Schuijer M, Wittebols K, Macours N, Stoll HP, Serruys PW, ARTS-II Investigators.
    J Am Coll Cardiol; 2008 Dec 09; 52(24):1957-67. PubMed ID: 19055986
    [Abstract] [Full Text] [Related]

  • 19. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial.
    Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, Buse JB, Cohen DJ, Mahoney E, Sleeper L, King S, Domanski M, McKinlay S, Fuster V.
    Am Heart J; 2008 Feb 09; 155(2):215-23. PubMed ID: 18215589
    [Abstract] [Full Text] [Related]

  • 20. Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial--a prospective, multicenter, randomized trial.
    Hirsch A, Nijveldt R, van der Vleuten PA, Biemond BJ, Doevendans PA, van Rossum AC, Tijssen JG, Zijlstra F, Piek JJ, HEBE investigators.
    Am Heart J; 2006 Sep 09; 152(3):434-41. PubMed ID: 16923409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.